Amgen, Cytokinetics, Servier Unveil New Results from Omecamtiv Mecarbil Study
November 18 2019 - 9:46AM
Dow Jones News
By Michael Dabaie
Amgen Inc. (AMGN), Cytokinetics Inc. (CYTK) and Servier
announced that new results from a Phase 2 trial showed omecamtiv
mecarbil in patients with heart failure with reduced ejection
fraction was associated with neutral or improved measures of
diastolic function.
In addition to previously reported improvements in cardiac
contractility measures, measures of diastolic function weren't
different from placebo and, for some measures, trended towards
improvement, the companies said.
In the COSMIC-HF trial, 448 patients were randomly assigned to
omecamtiv mecarbil or placebo in a double-blind fashion for 20
weeks.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 18, 2019 09:31 ET (14:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
